Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

Companies don't end up with outsize yields for no reason. Pfizer has several major patent expirations coming up. When a blockbuster drug loses patent protection, generic competition typically enters ...

In 2025, Pfizer paid roughly $9.8 billion in dividends. Through the first half of 2026, it paid roughly $4.8 billion. That's ...

Structural failures at MetroLoft, David Werner’s Midtown conversion could recast the value of unused air rights.

Singapore state investor sees opportunity in undervalued Chinese equities, life sciences and AI despite recent market headwinds ...

Both Pfizer and Gilead Sciences just flashed the same ominous technical warning while trading below analyst fair value.

New York City for decades has allowed developers to hire third-party inspectors to certify the safety of projects like 235 ...

The fund-raising values the company at $3.8 billion and underscores investor interest in using artificial intelligence to ...

Abbott Laboratories (NYSE: ABT) and Pfizer (NYSE: PFE) both delivered Q1 2026 beats, yet the market treats them differently.